Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Jerome Powell May Stay on Fed Board Amid Criminal Investigation, Court Documents Reveal 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
9 Tips for Avoiding Tax Season Cyber Scams 
California Court Rejects xAI Bid to Block AI Data Transparency Law 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.
